STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Companies Mid-Cap
scientist-2

CALC’s Promising Prospects in Severe Acute Kidney Injury: A Billion-Dollar Opportunity

byLiliana Vida
July 10, 2024
in Mid-Cap, Pharmaceuticals
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

First Patient Dosed in Phase 2 Trial

CALC has reached a significant milestone in its journey to address severe acute kidney injury (AKI), dosing the first patient in its Phase 2 trial. This advancement has led to a substantial increase in the projected target price (PT) for CALC’s stock, rising from $14 to $20. The company’s innovative approach to tackling AKI, a challenging and severe condition, is bolstered by recent positive Phase 2b results in acute pancreatitis (AP). These results not only showed improvements in severe renal failure but also broadened the supportive clinical evidence for CALC’s flagship drug, Auxora, in treating AKI.

Broadening Clinical Evidence and Potential Market Impact

AKI is a frequent inpatient complication that significantly increases the risks of mortality and respiratory failure, with current treatments limited to supportive care. The promising results from CALC’s AP study, which showed notable improvements in renal failure, have sparked interest in Auxora as a treatment for AKI. This interest could lead to ex-US regional partnerships in the second half of the year, providing potential financial support for the upcoming Phase 3 trial.

The KOURAGE trial, a double-blind study, will randomize 150 patients with Stage 2 or 3 AKI who also have acute hypoxemic respiratory failure (AHRF) and are receiving supplemental oxygen. Participants will receive either Auxora or a placebo. The primary endpoint of this trial is to measure the number of days patients are alive without requiring a ventilator or dialysis through day 30, with a secondary focus on the MAKE-90 diagnostic marker for chronic kidney disease (CKD). Top-line data from this trial is expected next year.

Financial Projections and Market Opportunity

The potential market for Auxora in treating AKI is estimated to be over $1 billion. Each year, approximately 500,000 patients in the United States are hospitalized with Stage 3 AKI, representing the segment with the greatest therapeutic need. If Auxora is priced at a net of $25,000 per course and used in just 10% of these cases, it would generate an estimated $1.3 billion in sales for CALC.

Increased Target Price and Future Catalysts

Reflecting the significant potential of Auxora in both AP and AKI, CALC’s PT has been raised to $20. This valuation is based on a risk-adjusted revenue multiples analysis, with estimated per-share values of approximately $8 for AP and $12 for AKI.

Looking ahead, several key catalysts are anticipated:

  • In the second half of 2024, additional data and details from the CARPO study are expected.
  • In 2025, an Investigational New Drug (IND) submission for an oral CRAC inhibitor (CRACi) targeting chronic pancreatitis and rheumatoid arthritis is planned.
  • Phase 2 topline results for AKI are also expected in 2025.

With these developments, CALC’s prospects in the challenging field of AKI treatment appear increasingly promising, positioning the company for significant market impact and financial success.

You might like this article:Discover Hidden Gems: 5 Undervalued Stocks You Should Look Into

Tags: BreakingMoversNewsStock Market
Previous Post

Discover Hidden Gems: 5 Undervalued Stocks You Should Look Into

Next Post

SoFi CEO Anthony Noto Discusses Company’s Future and Market Position on CNBC

Related Posts

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

byLuca Blaumann
August 5, 2025
0

Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock...

evtol

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

byLiliana Vida
August 4, 2025
0

Electric air taxi pioneer Joby expands passenger operations as Blade spins off medical transport arm into new public company Blade...

investing

GoPro and Krispy Kreme Surge as Meme Stock Frenzy Reignites

byLuca Blaumann
July 23, 2025
0

Retail traders push small caps higher despite shaky fundamentals A fresh wave of meme stock mania swept through markets on...

Next Post

SoFi CEO Anthony Noto Discusses Company’s Future and Market Position on CNBC

Latest News

Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

Based on Your Interest

trading-chart-2
Large-Cap

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

July 30, 2025
Aerospace & Defense

Palo Alto Networks Eyes $20B Deal for CyberArk

July 29, 2025
trading-chart
Ecommerece

AMD and Amazon: Two Titans Poised for Explosive Growth

July 28, 2025

Recommended

Entertainment

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

July 25, 2025
Aerospace & Defense

FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

July 24, 2025
Large-Cap

Intel Beats on Revenue, Misses on Earnings; Cuts Workforce by 15%

July 24, 2025
Brokerages

Accelerant Soars in NYSE Debut, Valued at $6.4 Billion

July 24, 2025
Distributor

GoPro and Krispy Kreme Surge as Meme Stock Frenzy Reignites

July 23, 2025
Stoxpo

Follow us on social media:

Highlights

  • Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations
  • Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast
  • Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom
  • Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk
  • Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations

August 6, 2025

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

August 5, 2025
trading-chart-2

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

August 4, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?